Canada markets closed

Adverum Biotechnologies, Inc. (ADVM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.3200-0.0400 (-1.69%)
At close: 4:00PM EDT
2.2900 -0.03 (-1.29%)
After hours: 06:07PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.3600
Open2.3427
Bid2.2900 x 3000
Ask2.3200 x 2900
Day's Range2.2900 - 2.4200
52 Week Range2.2300 - 19.2500
Volume1,725,558
Avg. Volume2,517,414
Market Cap227.209M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-1.3500
Earnings DateAug. 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.88
  • Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
    GlobeNewswire

    Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

    -- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host conference call and webcast today at 1:30 pm PT / 4:30 pm ET -- REDWOOD CITY, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided an update on the ADVM-

  • Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
    GlobeNewswire

    Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs

    REDWOOD CITY, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Jon Williams, Ph.D., as vice president, clinical affairs, effective immediately. Dr. Williams will provide scientific and technical expertise and leadership across Adverum’s clinical development program for ADVM-022, reporting to Julie Clark, M.D., chief medical off

  • Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade
    Zacks

    Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade

    Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).